Speedy generic approval may not benefit consumers as much as expected, Rotman model shows
Toronto — Faster approval times for generic drugs will get them into consumers’ hands quicker, but may not make the price any better, a pricing and marketing researcher has found.
A mathematical model created by Andrew Ching shows that fewer f…